Lexaria Bioscience Corp. (NASDAQ: LEXX) Set to Expedite Human and Animal Studies on DehydraTECH’s Effectiveness on GLP-1 Drugs Following Positive Results from Pilot Study
Lexaria, a global specialist in drug delivery platforms, just announced the final results from its recently completed human Pilot Study #1 on the effectiveness of its patented DehydraTECH(TM) technology on the oral delivery of GLP-1 drug, semaglutide The results showed improved delivery of semaglutide to the bloodstream, with the drug showing approximately 44% higher levels than the control 24 hours after ingestion of a single dose DehydraTECH GLP-1 processed semaglutide also proved to be better tolerated than the control, with the latter resulting in some cases of moderate nausea and diarrhea This milestone brings Lexaria closer to tapping into the…